Chris works primarily with Auroraís life science investments, specifically in the areas of drug discovery, biotechnology and medical devices. Previously, Chris trained in general surgery at Brigham and Womenís Hospital/Harvard Medical School where he was involved in the care of transplant, trauma, vascular cardiac and general surgical patients. He also has significant basic science research experience, including work on the molecular biology and genetics of apoptosis, and the transcriptional regulation of Interleukin-2 in human T-cells. While in business school, Chris worked in Corporate Development at Genzyme and performed independent research developing licensing strategies in Biogenís business development unit. He also formerly worked at Arthur D. Little, performing industry analysis for the biotechnology and pharmaceutical industries.
Chris is on the boards two of Aurora's life sciences companies, Hyperbranch and Neotropix, and serves as an observer on the boards of Argos, Regado, StemCo and Xsira.
Chris received a B.A. in Biology from Harvard University, his M.D. from Stanford University School of Medicine and an MBA from Harvard Business School.